Idelalisib Not Yet Recruiting Phase 2 Trials for Follicular Lymphoma (FL) Treatment

IndicationsStatusPurposePhase
Not Yet RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03890289Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma